Cancer procoagulant (CP) analysis in human WM 115 malignant melanoma cells in vitro

Kaplińska, Katarzyna; Różalski, Marcin; Krajewska, Urszula; Mielicki, Wojciech P.

doi:10.1016/j.thromres.2009.03.009

Cited by 3 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This ability was highly potentiated by the addition of exogenous factor Va, which functions as a co-factor for the enzyme factor Xa. It is known that two major procoagulants from malignant tissue are TF and a direct activator of coagulation factor X called CP [15,18,19]. TF is a transmembrane glycoprotein that acts as a receptor for nonactivated and activated factor VII and triggers the coagulation cascade, and it is possibly involved in cancer-related hypercoagulability.…”

Section: Discussionmentioning

confidence: 99%

“…This enzyme (in vitro) is a direct activator of the factor X, without the contribution of factor VII or any other cofactors. CP differs in physical, chemical, and enzymatic activities from other procoagulants [15,34].…”

Section: Discussionmentioning

confidence: 99%

“…High levels of circulating biomarkers resembling activated coagulation and fibrinolytic systems such as fibrinogen (F), fibrin(ogen) split products and DD have been associated with decreased survival for several tumor types in previous studies [11][12][13]. Researches on melanoma patients examining the relationship between activated hemostatic system and prognosis have yielded similar results [14][15][16]. Sufficient evidence of such an advantage has not been found for cancer patients in general.…”

Section: Introductionmentioning

confidence: 99%

“…It was observed that tumor cells strongly accelerate plasma coagulation as a result of: (i) expression of the blood clotting initiator protein, TF, and (ii) direct activation of prothrombin to thrombin by cells, as evidenced by hydrolysis of the natural substrate, F. This ability was highly potentiated by the addition of exogenous factor Va, which functions as a co-factor for the enzyme factor Xa [18]. It is known that two major procoagulants from malignant tissue, including melanoma, are TF and a direct activator of coagulation factor X called the cancer procoagulant (CP) [15]. It has been shown that F is a critical determinant of the metastatic potential of circulating tumor cells.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Clinical and prognostic significance of coagulation assays in melanoma

et al. 2012

View full text Add to dashboard Cite

The activation of coagulation and fibrinolysis is frequently found among cancer patients. Such tumors are considered to be associated with a higher risk of invasion, metastases, and eventually worse outcome. The aim of this study is to explore the clinical and prognostic value of blood coagulation tests for melanoma patients. Pretreatment blood coagulation tests including prothrombin time (PT), activated partial thromboplastin time (APTT), prothrombin activity (PTA), international normalized ratio (INR), D-dimer (DD), fibrinogen (F) levels, and platelet (PLT) counts were carried out. This prospective study included 61 melanoma patients [stage I-II (n=10), stage III (n=14), stage IV (n=37), M1c (n=26) disease], and 50 healthy controls. It included 34 (56%) men, median age 53 years, range 16-88 years. Over half of the patients (54%) were in the metastatic stage and most of them (70%) had M1c. The plasma level of pretreatment blood coagulation tests including DD, F, APTT, INR levels, and PLT counts showed a statistically significant difference between the patient and the control group (P<0.001 for all, but P=0.049 for INR). The levels of INR, DD, F, and PLT counts were higher and APTT was lower in the melanoma group, whereas the PT and PTA levels did not show any significant difference. There was a significant association between PT, PTA, INR, and PLT levels and the age of the patient. Patients with node metastasis in M0 disease had higher levels of PTA and PLT counts (P=0.002 and 0.048, respectively) and lower levels of PT and INR (P=0.056 and 0.046, respectively). The M1c patients tended to have higher plasma F levels (437 vs. 297 mg/dl, P=0.055) than M1a and M1b patients. The 1-year survival rate for all patients was 70%. In association with distant metastasis, advanced metastatic stage (M1c), elevated lactate dehydrogenase, and erythrocyte sedimentation rate, only elevated plasma F levels had a significantly adverse effect on survival among the coagulation parameters (P=0.031). The 1-year survival rates for patients with high and normal F levels were 58 and 88%, respectively. In conclusion, changes in the coagulation-fibrinolytic system are often present in melanoma and elevation in the plasma F level is associated with decreased survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical and prognostic significance of coagulation assays in melanoma

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Cancer procoagulant directly activates blood coagulation factor X in absence of activated factor VII. Cancer procoagulant is described in malignant and fetal tissues, but its genomic sequence is unknown [ 10 , 24 ]. Cancer procoagulant activity reduction as a result of the application of different cytostatics e.g.…”

Section: Discussionmentioning

confidence: 99%

Arsenic trioxide downregulates cancer procoagulant activity in MCF-7 and WM-115 cell lines in vitro

Hoffman¹,

Gizelska²,

Mirowski³

et al. 2015

View full text Add to dashboard Cite

The aim of the studyTo analyze human breast cancer cell line MCF-7 and human malignant melanoma cell line WM-115 in order to characterize the cellular expression of CP and to evaluate whether ATO may affect this activity, as well as the viability of the cells.Material and methodsThe inhibitory effect of arsenic trioxide on the proliferation of MCF-7 and WM-115 cells were measured with MTT test. The activity of cancer procoagulant after ATO exposure was determined by a specific three-stage chromogenic assay.ResultsATO decreased the CP activity in a dose- and time-dependent manner in MCF-7 cells with no effect on cell proliferation at the same time. However, it affected the CP activity of WM-115 cells in a different way. Reduction in CP activity was followed by an increase after 48 h incubation. The cells viability results showed dose-and time-correlated response within high arsenic concentrations.ConclusionsArsenic trioxide downregulates the CP expression in human breast cancer and melanoma cells.

show abstract

Hematological Issues in Critically Ill Patients with Cancer

Carlson

DeSancho

2010

Critical Care Clinics

View full text Add to dashboard Cite

Cancer procoagulant (CP) analysis in human WM 115 malignant melanoma cells in vitro

Cited by 3 publications

References 37 publications

Clinical and prognostic significance of coagulation assays in melanoma

Clinical and prognostic significance of coagulation assays in melanoma

Arsenic trioxide downregulates cancer procoagulant activity in MCF-7 and WM-115 cell lines in vitro

Hematological Issues in Critically Ill Patients with Cancer

Contact Info

Product

Resources

About